Develops medical technologies for point-of-care testing. Creates novel medical treatments for various disease indications. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 32% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 85.4× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 6% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $124K a year; the problem isn’t sales — it’s costs running above that number.
Over the last 12 months, company executives reported 35 buys and 24 sells. Management buying with its own money is usually read as a good sign.
A loss of $14.8M against $124K in annual sales.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, AIMD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AIMD’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.